Search filters

List of works by Sarah Waheed

A compound T60A and V122I heterozygosity in the transthyretin gene causing early onset severe cardiac amyloidosis

article

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

scientific article published on 3 November 2016

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

scientific article published on 3 October 2016

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

scientific article published on 21 October 2013

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

scientific article published on 10 June 2009

Correction: Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study

scientific article published on 30 March 2017

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients

scientific article

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

scientific article

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols

scientific article published on 13 February 2015

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

scientific article published on 23 April 2009

Hepatitis B reactivation in patients with multiple myeloma and isolated positive hepatitis B core antibody: a call for greater cognizance

scientific article published on July 2014

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

scientific article

High-risk myeloma: when to transplant-or not.

scientific article

Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols

scientific article published on 20 December 2008

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols ⬇️

scientific article published on October 13, 2010

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

scientific article published on 04 February 2014

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

scientific article

Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

scientific article

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 ⬇️

scientific article published on May 31, 2011

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

scientific article published on 10 January 2013

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

scientific article published on 19 April 2013

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance ⬇️

scientific article published on June 6, 2012

Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study

scientific article

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data ⬇️

scientific article published on June 24, 2012

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

scientific article

TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

scientific article published on 21 August 2009

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

scientific article published on 20 May 2008

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1

scientific article published on August 2012

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

scientific article

Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid

scientific article published on 9 August 2013

Paulina is supported by:

About Paulina

Help